59b04fe263488a722360926c1058da8b80c3d649dfb5b964920737925a5284aa

Net sales (USD, millions)

Cost of sales (USD, millions)

Gross profit (USD, millions)

Operating expenses: Distribution (USD, millions)

Operating expenses: Research and development (USD, millions)

Operating expenses: Selling (USD, millions)

Operating expenses: Administration (USD, millions)

Operating expenses: Impairment charges (USD, millions)

Operating expenses: Restructuring (USD, millions)

Operating expenses: Other operating income (expense), net (USD, millions)

Total operating expenses (USD, millions)

Operating income (loss) (USD, millions)

Interest expense, net (USD, millions)

Other income (expense), net (USD, millions)

Gain (loss) on extinguishment of debt (USD, millions)

Income (loss) from continuing operations before income taxes (USD, millions)

Income tax expense (benefit) (USD, millions)

Income (loss) from continuing operations (USD, millions)

Income (loss) from discontinued operations, net of tax (USD, millions)

Net income (loss) (USD, millions)

Basic Earnings (loss) per share - Continuing operations (USD per share)

Basic Earnings (loss) per share - Discontinued operations (USD per share)

Basic earnings (loss) per share (USD per share)

Diluted Earnings (loss) per share - Continuing operations (USD per share)

Diluted Earnings (loss) per share - Discontinued operations (USD per share)

Diluted earnings (loss) per share (USD per share)

Weighted-average shares outstanding - Basic (millions)

Weighted-average shares outstanding - Diluted (millions)

fe0d4449dbcfb634775ccfd083f9d85799dad8750c4255e8fa05f3814b1f64dc

Net cash from operating activities

Net cash for investing activities

Net cash for financing activities

Effect of exchange rate changes on cash and cash equivalents

Net increase (decrease) in cash and cash equivalents

Cash, cash equivalents and restricted cash of continuing operations, beginning of period

Cash, cash equivalents and restricted cash of continuing operations, end of period

Cash and cash equivalents held for sale, beginning of period

Less cash and cash equivalents held for sale, end of period

6ab9e67b2f4b677c2f50f1aca5388a41d8e580abee7a8d93ce3eadd8f47477ec

United States

Europe

- Ireland

All Other Countries

Total Revenue

b0c5b2930a1ca67566ea2f03a668bc4d3e0b0c5d65a9cf88491af4cca8ab0c9c

CSCA

- Upper Respiratory

- Digestive Health

- Nutrition

- Pain and Sleep-Aids

- Healthy Lifestyle

- Oral Care

- Skin Care

- Women's Health

- VMS

- Other CSCA

CSCI

- Other CSCI

9d6a3845f3e66e9e76d54f59535e604048f11f78d9809cbac730b53153348fee

PERRIGO Co (PRGO)

Financials